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OBJECTIVES The possible effect of plasma hemoglobin A1c (HbA1c) on the development of transplant
coronary artery disease (TxCAD) was investigated.
BACKGROUND Glucose intolerance is implicated as a risk factor for TxCAD. However, a relationship
between HbA1c and TxCAD has not been demonstrated.
METHODS Plasma HbA1c was measured in 151 adult patients undergoing routine annual coronary
angiography at a mean period of 4.1 years after heart transplantation. Intracoronary
ultrasound (ICUS) was also performed in 42 patients. Transplant CAD was graded by
angiography as none, mild (stenosis in any vessel 30%), moderate (31% to 69%), or severe
(70%) and was defined by ICUS as a mean intimal thickness (MIT) 0.3 mm in any
coronary artery segment. The association between TxCAD and established risk factors was
examined.
RESULTS Plasma HbA1c increased with the angiographic grade of TxCAD (5.6%, 5.8%, 6.4%, and
6.2% for none, mild, moderate, and severe disease, respectively; p  0.05 for none vs.
moderate or severe) and correlated with disease severity (r  0.24, p  0.05). The HbA1c
level was higher in patients with MIT 0.3 mm than in those with MIT 0.3 mm (6.4%
vs. 5.7%, p  0.05). Multivariate logistic regression analysis identified HbA1c as an
independent predictor of TxCAD, as detected by angiography or ICUS (odds ratios 1.9 and
2.4, 95% confidence intervals 1.5 to 6.3 [p  0.010] and 1.3 to 4.2 [p  0.005], respectively).
CONCLUSIONS Persistent glucose intolerance, as reflected by plasma HbA1c, is associated with the occurrence
of TxCAD and may play an important role in its pathogenesis. (J Am Coll Cardiol 2004;
43:1034–41) © 2004 by the American College of Cardiology FoundationM
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eransplant coronary artery disease (TxCAD) is the leading
ause of mortality in long-term survivors of heart transplan-
ation. Evidence suggests that risk factors for TxCAD
nclude hyperlipidemia (1,2), body mass index (BMI) (3,4),
nd donor age (5), with the rejection incidence (6,7) being
nly weakly correlated with TxCAD. Glucose intolerance
nd associated hyperlipidemia occur frequently as a conse-
uence of the action of immunosuppressive drugs used to
reat heart transplant patients (8). Studies of diabetes
ellitus (DM) in animal models have suggested that hy-
erglycemia may be an important factor in the pathogenesis
f TxCAD (1). However, little is known about the relation-
hip between hyperglycemia and the incidence and severity
f TxCAD in humans. Hemoglobin A1c (HbA1c) is a useful
ndex of glucose intolerance and hyperglycemia, even when
asting glucose concentrations are normal (9,10). We have
ow examined the hypothesis that the severity of glucose
ntolerance, as reflected by HbA1c concentration, correlates
ith the severity of TxCAD.
From the *Department of Cardiology, Stanford University, Stanford, California;
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ent of Cardiology, Nagoya University, Graduate School of Medicine, Nagoya; and
Nagoya University School of Health Sciences, Nagoya, Japan.
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tudy subjects. The study population comprised 151 con-
ecutive individuals (88 men and 63 women) who under-
ent heart transplantation at ages 16 to 61 years between
anuary 1990 and February 1995 at Stanford University
chool of Medicine. To reduce possible bias due to the
uration of post-transplant survival, we included only pa-
ients who were between 3.5 and 4.7 years (mean 4.1)
ost-transplantation. All subjects underwent coronary an-
iography and measurement of plasma HbA1c and serum
ipid concentrations. Intracoronary ultrasound (ICUS) was
erformed in a subgroup of 42 patients (27 men and 15
omen) aged 26 to 60 years. The demographics of the study
ubjects, including pretransplant heart disease, donor age,
mmunosuppressive treatment, and DM treated before or
fter transplantation, were recorded. Treated DM was
efined as any history of DM that required pharmacologic
ntervention with insulin or oral antidiabetic agents. Immu-
osuppression in all patients included prophylactic OKT3
uring the initial seven days after transplantation and
aintenance thereafter on a standard three-drug regimen of
yclosporine, prednisone, and azathioprine. In patients who
xperienced recurrent rejection episodes, azathioprine was
eplaced by mycophenolate mofetil, and, in some instances,
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March 17, 2004:1034–41 Hemoglobin A1c and Transplant Vasculopathyyclosporine was replaced by tacrolimus. All patients re-
eived antiplatelet therapy (aspirin 80 or 325 mg/day); 91
atients received hydroxymethylglutaryl coenzyme A reduc-
ase inhibitors; and 48 patients received diltiazem (120
g/day). The study was approved by the Institutional
eview Board of Stanford University School of Medicine,
nd written, informed consent was obtained from all
articipants.
ngiographic and ICUS classification. Routine surveil-
ance coronary angiograms obtained at a mean of 4.1
ears after transplantation were reviewed by two angiog-
aphers independently, and a consensus on the grading of
xCAD was reached, according to the following classi-
cation: none, mild (30% stenosis in any vessel),
oderate (31% to 69% stenosis), or severe (70% steno-
is or severe peripheral pruning). Coronary artery intimal
hickness was measured for the region between the left
ain coronary artery and the mid portion of the left
nterior descending coronary artery by ICUS at the time
f angiography in a subset of 42 patients. The mean
ntimal thickness (MIT) was calculated from the differ-
nce between the lumen area and total vessel area. On the
asis of the Stanford Classification (11), TxCAD was
efined as MIT 0.3 mm in any segment.
valuation of potential risk factors for TxCAD. Plasma
bA1c and glucose concentrations and serum concentra-
ions of triglycerides, total cholesterol, high-density li-
oprotein (HDL) cholesterol, and low-density lipopro-
ein (LDL) cholesterol were measured after a 12-h fast
n the day of coronary angiography. Donor age at the
ime of transplantation, increase in recipient BMI after
ransplantation, and rejection incidence were recorded.
he change (increase) in BMI after transplantation
BMI) was defined as BMI at the time of angiography
inus BMI at the time of transplantation. An average
ejection score for each patient was derived from Inter-
ational Society for Heart and Lung Transplantation
ISHLT) grading (0  0, 1A  1, 1B  2, 2  3, 3A 
, 3B  5, 4  6) and was calculated as the sum of the
ejection scores for each biopsy divided by the total
umber of biopsies. The cumulative doses (total drug
mount per kilogram of body weight) of cyclosporine,
Abbreviations and Acronyms
BMI  body mass index
CMV  cytomegalovirus
DM  diabetes mellitus
HbA1c  hemoglobin A1c
HDL  high-density lipoprotein
ICUS  intracoronary ultrasound
ISHLT  International Society for Heart and Lung
Transplantation
LDL  low-density lipoprotein
MIT  mean intimal thickness
TxCAD  transplant coronary artery diseaseacrolimus, and prednisone were also determined. ntatistical analysis. Data are expressed as the mean value
SD. The distributions of key variables, normal or
therwise, were evaluated by normal distribution plots
nd histograms to determine whether parametric or
onparametric tests should be used for analysis of group
ifferences. One-way analysis of variance was used to
ssess overall differences, and the Bonferroni correction
or multiple comparisons was applied to examine differ-
nces among the four groups stratified by angiographi-
ally determined TxCAD severity. Differences between
wo groups were assessed by the unpaired t test or
hi-squared test. The Spearman correlation coefficient
as determined to evaluate whether TxCAD severity, as
stimated from angiograms, was correlated with the
lasma concentration of HbA1c.
Univariate logistic regression analysis was used to select
he potential independent predictive factors for TxCAD
defined as 70% stenosis by angiography or MIT 0.3
m by ICUS) for inclusion in multivariate analysis. The
ovariables examined included gender and the occurrence of
M treated before or after transplantation as categorical
ariables, and donor age, recipient age, baseline BMI,
BMI, average rejection score, and fasting levels of HbA1c,
lucose, triglycerides, total cholesterol, HDL cholesterol,
nd LDL cholesterol as continuous variables. Univariate
redictors of TxCAD, as determined by angiography or
CUS, with a p value of 0.05, were entered into a
ultivariate logistic regression model with stepwise selec-
ion. Differences were considered statistically significant at p
0.05.
To assess the correlation between TxCAD identified by
ngiography and that identified by ICUS, we analyzed the
elationship between stenosis determined by angiography
nd MIT determined by ICUS with the use of Pearson’s
orrelation coefficient. In addition, the correlation between
he TxCAD classifications derived from angiography and
hose from ICUS was evaluated with the Spearman rank
orrelation coefficient. The MIT cutoff value of 0.3 mm,
etermined by ICUS, was used to differentiate between
ngiographically determined none or mild (30% stenosis)
xCAD and moderate or severe (31% stenosis) TxCAD,
s well as between none/mild/moderate (69% stenosis)
nd severe (70% stenosis) TxCAD. The sensitivity (true
ositive/[true positive  false negative]), specificity (true
egative/[true negative  false positive]), and predictive
ccuracy ([true positive  true negative]/total group) were
etermined and expressed as percentages.
Linear regression analysis was used to determine whether
correlation existed between the plasma HbA1c concentra-
ion and cumulative doses of cyclosporine, tacrolimus, or
rednisone.
ESULTS
ontinuous variables analyzed in the present study were
ormally distributed. Demographic characteristics of the
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Hemoglobin A1c and Transplant Vasculopathy March 17, 2004:1034–41tudy subjects did not differ significantly among the
roups stratified by either the grade of TxCAD deter-
ined angiographically (Table 1) or MIT determined by
CUS (Table 2).
Table 1. Characteristics of Study Subjects Stra
Disease as Determined by Angiography
Characteristic
None
(n  49)
M
(n
Recipient age (yrs)* 41.1  9.4 38.7
Male/female 30/19 16
Donor age (yrs) 26.0  10.0 26.5
Baseline BMI (kg/m2)* 23.7  3.4 24.3
Primary diagnosis (%)
IDCM 44.9 4
IHD 34.7 3
Other 20.4 1
Drugs (%)
Cyclosporine 79.6 7
Tacrolimus 20.4 2
Azathioprine 73.6 7
MMF 20.7 2
Prednisone 61.2 5
HMG-CoA RI 67.3 6
Diltiazem 28.6 3
Treated DM (%)
Pretransplant 8.2
Post-transplant 14.3 1
*Values at the time of heart transplantation. Data are prese
subgroup.
BMI  body mass index; DM  diabetes mellitus; HM
IDCM  idiopathic cardiomyopathy; IHD  ischemic hear
coronary artery disease.
able 2. Characteristics of Study Subjects Stratified by Mean
ntimal Thickness, as Determined by Intracoronary Ultrasound
Characteristic
MIT
p Value
<0.3 mm
(n  20)
>0.3 mm
(n  22)
ecipient age (yrs)* 48.8  6.9 54.9  5.3 0.066
ale/female 14/6 13/9 0.31
onor age (yrs) 30.9  8.9 36.4  9.8 0.065
aseline BMI (kg/m2)* 24.2  4.1 23.9  3.5 0.80
rimary diagnosis (%)
IDCM 50.0 59.1 0.65
IHD 50.0 39.3 0.46
Other 0 1.6 0.025
rugs (%)
Cyclosporine 75.0 72.3 0.62
Tacrolimus 25.0 27.3 0.49
Azathioprine 80.0 68.1 0.34
MMF 20.0 31.9 0.40
Prednisone 40.0 50.0 0.73
HMG-CoA RI 65.0 63.6 0.43
Diltiazem 30.0 45.5 0.31
reated DM (%)
Pretransplant 10.0 18.2 0.92
Post-transplant 15.0 18.2 0.44
Values at the time of heart transplantation. Data are presented as the mean value 
D or percentage of patients in each subgroup.IMIT  mean intimal thickness; other abbreviations as in Table 1.omparison of fasting HbA1c, lipid, and glucose concen-
rations, as well as BMI and drug doses, among pa-
ients stratified by TxCAD severity. The fasting concen-
rations of HbA1c, lipids, and glucose, as well as BMI, for
he study subjects are presented according to angiographic
Table 3) or ICUS findings (Table 4). The plasma concen-
ration of HbA1c was significantly higher in patients with
oderate or severe TxCAD, as determined by angiography,
han in those with no disease. It was also significantly higher
n patients with moderate to severe TxCAD than in those
ith none/mild TxCAD. The severity of TxCAD, as
etermined by angiography, was correlated with the plasma
oncentration of HbA1c (Spearman r  0.24, p  0.0434)
Fig. 1). The BMI was significantly greater in patients
ith moderate or severe TxCAD than in those with no
isease or mild TxCAD. Similarly, BMI in patients with
oderate to severe TxCAD was greater than that in those
ith none/mild TxCAD. Both the plasma HbA1c concen-
ration and BMI were significantly greater in subjects with
IT 0.3 mm than in those with MIT 0.3 mm. The
umulative doses of drugs known to affect glucose tolerance
cyclosporine, tacrolimus, and prednisone) showed no cor-
elation with the plasma concentration of HbA1c or with
xCAD (data not shown).
ssociation between established risk factors and TxCAD.
ultiple logistic regression analysis was performed for
xCAD, defined as either 70% stenosis determined by
ngiography (Table 5) or MIT 0.3 mm determined by
by Grade of Transplant Coronary Artery
e of TxCAD
p Value
Moderate
(n  41)
Severe
(n  28)
1 42.3  9.6 43.4  11.2 0.24
24/19 18/10 0.74
2 27.0  9.8 31.8  12.2 0.09
4 24.1  3.6 24.5  4.1 0.72
46.5 53.6 0.65
34.9 30.7 0.46
18.6 15.7 0.25
79.1 71.4 0.62
20.9 28.6 0.49
79.1 67.1 0.12
20.9 25.5 0.53
46.5 53.6 0.73
51.2 60.7 0.48
30.2 35.7 0.78
16.3 13.9 0.65
13.9 17.9 0.90
s the mean value  SD or percentage of patients in each
oA RI  hydroxymethylglutary-CoA reductase inhibitors;
se; MMF  mycophenolate mofetil; TxCAD  transplanttified
Grad
ild
 30)
 7.
/15
 8.
 3.
8.4
8.9
2.7
3.3
5.3
4.1
2.9
1.6
1.2
5.5
9.7
9.3
nted a
G-C
t diseaCUS (Table 6), as the dependent variable and for risk
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March 17, 2004:1034–41 Hemoglobin A1c and Transplant Vasculopathyactors that showed a significant association with TxCAD
dentified by angiography or ICUS on univariate analysis.
mong the variables included in the multivariate analysis,
nly the plasma HbA1c concentration was significantly
ssociated with TxCAD identified by angiography. Simi-
arly, only the plasma HbA1c concentration and, to a lesser
xtent, BMI were significantly associated with TxCAD
dentified by ICUS on multivariate analysis.
oncordance between TxCAD identified by angiography
r ICUS. Pearson’s correlation analysis revealed that the
ercent stenosis determined by coronary angiography was
orrelated with MIT determined by ICUS (r  0.614, p 
.0001) (Fig. 2A). The angiographic stratification of
xCAD was also correlated with the classification of
xCAD as MIT 0.3 mm by ICUS (Spearman r  0.74,
 0.0001) (Fig. 2B). The MIT cutoff value of 0.3 mm,
s determined by ICUS, was used to differentiate between
atients with none/mild TxCAD and those with moderate
o severe TxCAD, as determined by angiography, yielding
able 3. Plasma Concentrations of Hemoglobin A1c and Glucose
tratified by Grade of Transplant Coronary Artery Disease as De
Variable
None
(n  49)
Mild
(n  3
None/Mild (n  80)
bA1c (%) 5.6  1.0* 5.8 
5.7  1.0†
lucose (mg/dl) 132.4  70.1 135.7 
133.7  66.3
riglycerides (mg/dl) 221.8  53.7 231.6 
227.9  68.8
otal cholesterol (mg/dl) 188.5  52.5 203.6 
195.6  66.4
DL cholesterol (mg/dl) 45.9  12.1 42.0 
44.2  11.5
DL cholesterol (mg/dl) 128.6  40.0 151.3 
140.0  41.7
BMI (kg/m2) 0.3  5.0‡ 0.4 
0.4  5.0§
p  0.05 versus either moderate or severe. †p  0.05 versus moderate/severe. ‡p
oncentrations were determined under fasting conditions. Data are presented as the
HbA1c  hemoglobin A1c; HDL and LDL  high- and low-density lipoprotein
Table 4. Plasma Concentrations of Hemoglobi
and Change in Body Mass Index Stratified by
Intracoronary Utrasound
Variable
<0.3 mm
(n  20
HbA1c (%) 5.7  1.
Glucose (mg/dl) 122.5  48
Triglycerides (mg/dl) 221.8  53
Total cholesterol (mg/dl) 183.2  52
HDL cholesterol (mg/dl) 50.1  13
LDL cholesterol (mg/dl) 138.6  41
BMI (kg/m2) 0.2  4.
*p  0.05. Data are presented as the mean value  SD.
Abbreviations as in Tables 1 and 3.ensitivity, specificity, and predictive accuracy values of
4.4% (17 of 18 subjects), 79.2% (19 of 24 subjects), and
5.7% (36 of 42 subjects), respectively. Similarly, differen-
iation between patients with none/mild/moderate TxCAD
nd those with severe TxCAD revealed sensitivity, specific-
ty, and predictive accuracy values of 100% (9 of 9 subjects),
0.6% (20 of 33 subjects), and 69.0% (29 of 42 subjects),
espectively.
ISCUSSION
ransplant CAD is the leading cause of death or retrans-
lantation among long-term survivors of heart transplanta-
ion. Up to 50% of transplant recipients have angiographi-
ally detectable CAD, and even more patients exhibit
ntimal thickening on examination by ICUS, five years after
ransplantation (12–14). We have now investigated risk
actors for development of TxCAD and demonstrate a
orrelation between glucose intolerance, as reflected by
um Lipid Concentrations, and Change in Body Mass Index
ined by Angiography
de of TxCAD
p Value
Moderate
(n  43)
Severe
(n  28)
Moderate/Severe (n  71)
6.4  1.8 6.2  1.6 0.08
6.3  1.7 0.012
129.2  56.7 124.8  30.0 0.90
127.5  47.4 0.52
224.7  65.6 202.5  46.6 0.73
226.3  59.9 0.74
195.6  66.4 202.5  46.6 0.72
198.3  59.1 0.74
43.2  7.6 40.7  6.2 0.14
42.1  7.1 0.21
137.8  45.4 135.0  58.7 0.31
136.7  50.8 0.70
2.1  5.1 3.4  4.6 0.035
2.6  4.9 0.0059
5 versus either moderate or severe. §p  0.01 versus moderate/severe. All analyte
value  SD.
ectively; other abbreviations as in Table 1.
c and Glucose, Serum Lipid Concentrations,
n Intimal Thickness, as Determined by
MIT
p Value
>0.3 mm
(n  22)
6.4  2.1 0.041*
129.4  49.9 0.68
223.2  52.5 0.86
180.3  57.2 0.86
45.0  4.4 0.11
135.7  69.6 0.88
3.5  4.8 0.015*, Ser
term
Gra
1)
1.0
61.0
76.1
63.6
10.5
40.9
5.0†
 0.0
mean
, respn A1
Mea
)
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Hemoglobin A1c and Transplant Vasculopathy March 17, 2004:1034–41ncreased plasma HbA1c levels, and the occurrence of
xCAD. The results of the present study are consistent
ith our previous observations linking aspects of insulin
esistance syndrome to the development of TxCAD (15).
pecifically, we showed that plasma glucose and insulin
oncentrations measured 2 h after oral challenge with 75 g
f glucose were significantly higher in patients with
xCAD than in those without the disease (8). Our present
esults further suggest that, even in the presence of near-
ormal fasting glucose levels, chronic mild elevation of
lasma glucose in heart transplant patients may contribute
o the development of TxCAD.
Although some studies have demonstrated a high preva-
ence of glucose intolerance among TxCAD patients (8,16),
any others have failed to show a correlation between
igure 1. Relationship between the grade of TxCAD stratified by coronary
ngiography and plasma HbA1c concentration.
able 5. Univariate and Multiple Logistic Regression Analysis
f Risk Factors for Transplant Coronary Artery Disease, as
dentified by Angiography
Variable OR (95% CI) p Value
nivariate logistic regression analysis
Gender (male) 2.8 (1.4–9.2) 0.73
Pretransplant treated DM 1.1 (0.5–2.9) 0.079
Post-transplant treated DM 1.8 (1.05–3.3) 0.61
Donor age (yrs) 2.3 (1.6–3.3) 0.002
Recipient age (yrs) 1.1 (0.6–2.0) 0.81
Baseline BMI (kg/m2) 1.2 (1.0–1.3) 0.58
BMI (kg/m2) 4.1 (1.4–14.8) 0.02
Rejection score 1.7 (0.9–3.4) 0.02
HbA1c (%) 2.08 (1.3–3.3) 0.002
Glucose (mg/dl) 1.2 (0.29–4.9) 0.71
Triglycerides (mg/dl) 1.9 (1.3–2.9) 0.004
Total cholesterol (mg/dl) 1.65 (1.06–2.6) 0.03
HDL cholesterol (mg/dl) 1.4 (0.46–4.4) 0.56
LDL cholesterol (mg/dl) 0.89 (0.7–1.3) 0.9
ultiple logistic regression analysis
Donor age (yrs) 0.99 (0.94–1.05) 0.73
BMI (kg/m2) 1.34 (0.92–3.4) 0.059
Rejection score 0.98 (0.95–1.02) 0.98
HbA1c (%) 1.9 (1.5–6.3) 0.010
Triglycerides (mg/dl) 0.99 (0.91–1.25) 0.74
Total cholesterol (mg/dl) 1.00 (0.97–1.03) 0.99iI  confidence interval; OR  odds ratio; other abbreviations as in Tables 1 and 3.xCAD and fasting blood glucose concentration. One
ossible reason for this discrepancy is a lack of consistency
n evaluation of glucose intolerance in transplant patients.
he sporadic measurements of fasting blood glucose in such
ndividuals in the transplant clinic setting are unreliable for
ssessing long-term glucose intolerance, because the results
ay vary markedly depending on both the patient’s medical
egimen and the time since transplantation. Although
esting of oral glucose tolerance is a better approach, it is
abor-intensive. However, several studies (9,10) have shown
hat HbA1c is a reliable index of persistent hyperglycemia.
We have now used HbA1c as a measure of persistent
yperglycemia to investigate whether the severity of glucose
ntolerance is correlated with the occurrence and severity of
xCAD, as assessed by either angiography or ICUS. In
ddition to postprandial hyperglycemia, obesity is an im-
ortant feature of insulin resistance syndrome. In the
resent study, we found that BMI was greater in patients
ith TxCAD than in those without it, even though BMI at
he time of transplantation did not differ significantly
etween the two groups. This observation is consistent with
he previous demonstration that weight gain after transplan-
ation is an important risk factor for TxCAD (16). An
ncrease in BMI is consistent with the insulin resistance
yndrome induced by immunosuppressive drugs in heart
ransplant patients (15). The importance of obesity in the
ontext of insulin resistance as a risk factor for cardiovas-
ular disease in the general population has also been
mphasized (17,18).
We did not detect a significant correlation between
xCAD and any of the lipid abnormalities previously
able 6. Univariate and Multiple Logistic Regression Analysis
f Risk Factors for Transplant Coronary Artery Disease, as
dentified by Intracoronary Ultrasound
Variable OR (95% CI) p Value
nivariate logistic regression analysis
Gender (male) 1.75 (0.54–5.6) 0.34
Pretransplant treated DM 1.4 (0.42–5.2) 0.09
Post-transplant treated DM 1.5 (0.47–4.7) 0.42
Donor age (yrs) 4.2 (1.1–16.3) 0.019
Recipient age (yrs) 0.92 (0.29–2.86) 0.88
Baseline BMI (kg/m2) 1.8 (1.05–3.3) 0.18
BMI (kg/m2) 2.0 (1.3–3.1) 0.001
Rejection score 0.71 (0.52–4.4) 0.006
HbA1c (%) 2.2 (1.5–3.2) 0.001
Glucose (mg/dl) 1.6 (1.3–1.8) 0.41
Triglycerides (mg/dl) 1.1 (0.6–2.0) 0.059
Total cholesterol (mg/dl) 1.5 (1.03–2.3) 0.009
HDL cholesterol (mg/dl) 1.6 (0.46–6.4) 0.08
LDL cholesterol (mg/dl) 1.2 (0.26–6.3) 0.28
ultiple logistic regression analysis
Donor age (yrs) 1.03 (1.00–1.12) 0.73
BMI (kg/m2) 1.5 (1.0–2.1) 0.041
Rejection score 0.62 (0.25–1.98) 0.98
HbA1c (%) 2.4 (1.3–4.2) 0.0043
Total cholesterol (mg/dl) 0.99 (0.98–1.01) 0.99
bbreviations as in Tables 1, 3, and 5.dentified as risk factors for this condition. This discrepancy
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March 17, 2004:1034–41 Hemoglobin A1c and Transplant Vasculopathyight be due to the fact that statin therapy was routinely
nitiated early after heart transplantation in all of the
atients in the present study. However, the mean serum
oncentrations of LDL cholesterol and triglycerides in the
tudy subjects were higher than those outlined in the
ational Cholesterol Education Program (NCEP) guide-
ines for patients at high risk of CAD (17). The importance
f hyperglycemia as a risk factor for vascular disease,
articularly in the presence of hyperlipidemia, has been
emonstrated outside the context of transplantation (17–
9). Our results suggest a similar association for TxCAD.
pecifically, in our multiple logistic regression analysis,
bA1c was the only significant predictor of TxCAD,
efined as 70% stenosis, as revealed by angiography, and
t was the most powerful predictor of TxCAD, defined as
IT 0.3 mm, as determined by ICUS, in a model that
ncluded donor age, rejection score, BMI, and serum total
holesterol.
tudy limitations. One of the limitations of this or any
tudy of TxCAD is the definition of the disease itself. One
r more years after heart transplantation, most patients
how ultrasound evidence of intimal thickening that is not
pparent on the angiogram (11); the “gold standard” for
iagnosis of this clinical entity is therefore ICUS. However,
nly a minority of the patients in the present study under-
ent ICUS; inclusion in the study was based on conven-
igure 2. Relationships between percent stenosis determined by coronary
ngiography and mean intimal thickness (MIT) determined by intracoro-
ary ultrasound (ICUS) (A) and between the severity of transplant
oronary artery disease (TxCAD) stratified by coronary angiography and
IT determined by ICUS (B).ional coronary angiography. In addition, only the region erom the left main coronary artery to the mid portion of the
eft anterior descending coronary artery was examined in the
atients who underwent ICUS in our study. Furthermore,
easurements of intimal thickness were taken at a limited
umber of sites in each patient, thus reflecting the disease
rocess only at these sites. However, TxCAD is diffuse in
ature (20,21), so that observation of the left anterior
escending coronary artery likely provides a reasonable
ndication of the extent and severity of the disease through-
ut the remainder of the coronary arterial tree, correspond-
ng to angiographic severity.
These limitations are mitigated by the significant corre-
ation of MIT with the angiographic data in the patients of
he present study. Although the presence of any angio-
raphically detectable disease has been proposed as a pre-
erred cutoff for diagnosis of TxCAD, our analysis showed
high degree of concordance between intimal thickening
0.3 mm) and the presence of mild, moderate, or severe
ngiographic disease. Our rationale for not using any
ngiographic stenosis as the cutoff is further supported by
he observation that there was less concordance between
ntimal thickening and any angiographic disease, suggesting
hat intimal thickening may not have been present in
ngiographic lesions with 30% stenosis, and that these
inor lesions might be due to coronary spasm.
Another limitation of our study is that it was not able to
ddress the outcome of TxCAD. Furthermore, the patients
ncluded in the analysis constitute a selected group in that
hey had survived for 3.5 years after transplantation, and
hat individuals who developed TxCAD later than 4.7 years
fter transplantation were also excluded.
Classifications of coronary disease severity allow grouping
f patients according to the degree of vessel wall involve-
ent but do not take into account the fact that the disease
rocess is not categorical. An important aspect of any
iscontinuous classification system is selection of cutoff
alues between grades. The present study relied predomi-
antly on the classification determined by conventional
ngiography. Our results might therefore have been biased,
ecause focal epicardial stenoses may have been the result of
onventional atherosclerosis or even present in the donor
eart at the time of transplantation; thus, such stenoses may
r may not have been related to the immune phenomena
hought to underlie much TxCAD. Our rationale for use of
ngiographic classification in this retrospective study was
ased on the fact that most transplant patients undergo
oronary angiography and therefore could be included to
llow a robust statistical analysis of risk factors. Intravascular
ltrasound data were available only for a subset of patients,
ecause this procedure is not routinely performed, even
hough it is more sensitive for the detection of TxCAD.
The definition of no disease as lesions with 30%
tenosis is, strictly speaking, incorrect, given that one or
ore years after heart transplantation, most patients show
ltrasound evidence of intimal thickening that is not appar-
nt on the angiogram (13). The differentiation between
m
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Hemoglobin A1c and Transplant Vasculopathy March 17, 2004:1034–41oderate (31% to 69% stenosis) and severe (70% stenosis)
xCAD is also arbitrary and does not necessarily correlate
ith the ischemic potential of lesions, as has been shown by
he poor correlation between stress-induced myocardial
schemia and angiographic findings in heart transplant
atients (22). In the field of clinical cardiology, however, the
se of such nomenclature is accepted for communication of
ata and for decision-making. We defined severe TxCAD,
s identified by angiography, as 70% stenosis or the
resence of severe peripheral pruning. The pathophysiology
f the diffuse process of pruning is uncertain. It may
rimarily represent an immune-mediated rejection-like pro-
ess unlike conventional atherosclerosis. Indeed, TxCAD
hat develops early after transplantation progresses rapidly
nd portends a poor prognosis, consistent with an immune-
ediated process (23).
Although the plasma concentration of HbA1c was corre-
ated with the severity of TxCAD identified by angiogra-
hy, the correlation was relatively weak (Spearman r 0.24,
 0.0434), possibly as a result of the small number of
atients in the study. It will thus be important to perform a
ulticenter study to confirm this potential association
etween glucose intolerance and TxCAD.
We used an average rejection score for each patient
erived from ISHLT grading as a potential risk factor for
xCAD. The use of such a score may introduce an
versimplification into our analysis, because it is likely that
iopsies of grade 2 or higher differ qualitatively (assuming
andom distribution of sampling error), and that the re-
ponses of the clinician to grade 2 or 3A biopsy differ,
ossibly affecting prescribed medications and, consequently,
lucose tolerance.
Another important limitation of our study is that it did
ot address cytomegalovirus (CMV) as a potential covari-
ble in the risk analysis. Infection with CMV is a risk factor
or TxCAD, and prophylaxis with antiviral agents, such as
anciclovir, has been shown to reduce the incidence of
xCAD (24). In contrast to CMV disease that develops
fter transplantation, the correlation between pretransplant
MV serology and TxCAD is controversial. Given that we
o not routinely measure CMV activation by culture,
ntigenemia tests, or polymerase chain reaction, we were
nable to examine the correlation of CMV disease or
nfection with TxCAD in the current cohort of patients.
rom a pathophysiologic perspective, such an analysis might
e important because of the propensity for CMV to induce
hronic inflammation. Our decision not to include the
MV serostatus of donors and recipients in the present
nalysis was partly based on our previous studies showing a
orrelation between donor positivity and TxCAD in uni-
ariate but not multivariate analysis (16).
onclusions. Our results indicate that persistent glucose
ntolerance, as reflected by an increased plasma level of
bA1c, is significantly correlated with the occurrence of
xCAD, providing further evidence that glucose intoler-nce plays a role in the disease process. The discordanceetween HbA1c and fasting glucose concentrations suggests
hat strategies that target postprandial hyperglycemia are
arranted. Our observation that BMI was also associated
ith the occurrence of TxCAD merits further study, and
pproaches aimed at preventing this post-transplant in-
rease in BMI should be assessed. Finally, prospective
tudies are needed to determine which immunosuppressive
rugs are least likely to induce this clinically important
bnormality.
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